In this study, we showed for the first time, that systemic blockade of the TLR4–MD2 complex with an anti-TLR4 neutralizing antibody significantly lowers BP in the STZ-induced diabetic model (Fig. 1), which is an animal model of type 1 diabetes that may have a predisposition to developing a mild elevation in BP23–25. Here, LY96 is linked to type 1 diabetes mellitus.